Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: IBIO123Other: Placebo
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Immune Biosolutions Inc
- Target Recruit Count
- 200
- Registration Number
- NCT05639166
- Locations
- 🇿🇦
Jongaie Research, Pretoria West, Pretoria, South Africa
🇺🇦Central City Clinical Hospital of Chernivtsi City Council, Chernivtsi, Chernivetska, Ukraine
🇺🇦City Clinical Hospital #1 of Ivano-Frankivsk City Council, Ivano-Frankivs'k, Ivano-Frankivsk Oblast, Ukraine
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Other: PlaceboBiological: IBIO123
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Immune Biosolutions Inc
- Target Recruit Count
- 123
- Registration Number
- NCT05303376
- Locations
- 🇿🇦
JOHESE UNITAS Hospital, Lyttelton, Centurion, South Africa
🇿🇦JOHESE ZAH Hospital, Pretoria, Gauteng, South Africa
🇺🇦Hospital №1" of the Zhytomyr City Council, Zhytomyr, Zhytomyrs'ka Oblast, Ukraine
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: IBIO123Other: Placebo
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Immune Biosolutions Inc
- Target Recruit Count
- 162
- Registration Number
- NCT05298813
- Locations
- 🇧🇷
Santa Casa de Misercórdia de Passos, Passos, Minas Gerais, Brazil
🇿🇦Durban International Clinical Research, Enhancing Care Foundation, Durban, Kwazulu-Natal, South Africa
🇧🇷Instituto Brasil de Pesquisa Clinica, Gloria, Rio De Janeiro, Brazil
© Copyright 2025. All Rights Reserved by MedPath